Geron Corporation

ladies and gentlemen this is the operator today's conference call will begin in two minutes until that time your lines will again be placed on hold thank you for your patience again ladies and gentlemen this is the operator today's conference call will begin in two minutes until that time your lines will again be placed on hold thank you for your patience THE END THE END

Ladies and gentlemen, thank you for standing by and welcome to the Q2 2021 Duron Earnings Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session and instructions will follow at that time. If anyone should require assistance during the conference, please press star zero on your touch-tone telephone. As a reminder, this conference call is being recorded. I would like to turn the conference over to your host, Ms. Olivia Bloom. Please go ahead.

All right, thank you very much, Grace. And good afternoon, everyone. Welcome to this conference call to discuss updates on our ongoing Immatelstat Phase III clinical trials, as well as second quarter financial results. I am joined today by Dr. John Scarlett, Geron's Chairman and Chief Executive Officer, Dr. Alexander Rizzo, Geron's Executive Vice President and Chief Medical Officer, and Anil Kapoor, Geron's Executive Vice President of Corporate Strategy and Chief Commercial Officer. After the market closed today, we announced updates on our Emerge Phase III clinical trials and financial results for our second quarter via press release, which is available on our website. In addition, an archive of this webcast will be available on our website for 30 days, including the slides being presented today. Before we begin, please note that during the course of this presentation and question and answer session, we will make forward-looking statements regarding future events, performance, plans, expectations, and other projections, including those relating to the therapeutic potential of and potential regulatory approval of Immatel-STAT, anticipated clinical and commercial events and related timelines, the sufficiency of Geron's financial resources, and other statements that are not historical fact. Actual events or results could differ materially. We refer you to the discussions under the heading Risk Factors in Jerome's quarterly report on Form 10-Q for the quarter ended June 30, 2021, which contains and identifies important factors that could cause actual results to differ materially from those contained in the forward-looking statement. We undertake no duty or obligation to update our forward-looking statement. And now, I will turn the call over to Dr. Scarlett. Chip?